Peking University First Hospital clinical trial pipeline

11 trials changed in the last 30 days: 0 stopped, 9 with notable changes, 2 with minor changes only.

1. Notable

   Application of 18F-G1 PET/CT Targeting Granzyme B in the…Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

   Primary completion pushed from Dec 31, 2026 to Dec 1, 2028

   Also in this update: Primary endpoint(s) modified; Recruitment opened

   Peking University First Hospital·Not specified· NCT07039474· Registry history of NCT07039474 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

2. Notable

   FAP-targeting PET/CT for Noninvasive Monitoring of Renal Fibrosis

   Primary completion pushed from May 10, 2026 to May 10, 2027

   Peking University First Hospital·Not applicable· NCT06563765· Registry history of NCT06563765 on ClinicalTrials.gov (opens the registry)

   Updated Sep 25, 2026

3. Notable

   Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in…Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

   Primary and study completion pushed from Dec 2025 to Dec 2027

   Peking University First Hospital·Not specified· NCT05683353· Registry history of NCT05683353 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

4. Notable

   Dexmedetomidine-esketamine and tDCS · Neurocognitive Complications…Dexmedetomidine-esketamine and tDCS · Neurocognitive Complications After Surgery

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 1160 → 1996 participants; Primary completion pushed from Jun 2029 to Dec 2029

   Peking University First Hospital·Phase 4· NCT07576517· Registry history of NCT07576517 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

5. Notable

   MOIPAD · Multimodal Ophthalmic Imaging and Plasma Biomarkers for…MOIPAD · Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

   Primary endpoint(s) modified

   Peking University First Hospital·Not specified· NCT06924359· Registry history of NCT06924359 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

6. Notable

   LUXUS41 · Disitamab Vedotin Plus Radiotherapy for Adjuvant…LUXUS41 · Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

   Phase changed: Phase 2 → Phase 3

   Also in this update: Recruitment opened

   Peking University First Hospital·Phase 3· NCT07498907· Registry history of NCT07498907 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

7. Notable

   GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders

   Recruitment opened

   Peking University First Hospital·Phase 1· NCT07660939· Registry history of NCT07660939 on ClinicalTrials.gov (opens the registry)

   Updated Sep 28, 2026

8. Notable

   Minimal Residual Disease · Systemic Light Chain Amyloidosis

   Recruitment opened

   Peking University First Hospital·Not applicable· NCT07215494· Registry history of NCT07215494 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

9. Notable

   Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive…Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery

   Enrollment increased: 1160 → 1996 participants

   Also in this update: Primary completion pushed from Jun 2030 to Dec 2030; Study completion pushed from Jun 2031 to Dec 2031

   Peking University First Hospital·Phase 4· NCT07576543· Registry history of NCT07576543 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.